Pharmaron Beijing Co., Ltd. provided earnings guidance for the financial year ended December 31, 2023. For the period, the company expects the revenue in the range of RMB 11,395.5799 million to RMB 11,703.5685 million. Growth compared with the same period of last year is 11% - 14%.

Net profit attributable to owners of the parent is expected to be in the range of RMB 1,567.0488 million to RMB 1,635.7790 million. Growth compared with the same period of last year of 14% to ­19%. Basic earnings per share is expected to be in the range of RMB 0.8841 to ­0.9229.